# Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 Supplementation: An Exploratory, Randomized, Placebo-Controlled Trial of Endocannabinoid and Inflammatory Responses in Female Dancers

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/research/endocannabinoid-system-for-inflammation-randomized-controlled-trial/
> **Published:** 2026-10-26T11:14:12-04:00 | **Last Modified / Clinically Audited:** 2026-10-26T11:14:12-04:00
> **Clinical Summary:** This study looked at young women who train as professional dancers. It made no clear difference.

---

The anandamide (AEA) and lipopolysaccharide (LPS) interaction is gaining attention, but evidence on the influence of probiotics on endocannabinoid system (ECS) biomarkers remains limited. This study (NCT05567653) investigated the effects of 12-week supplementation with Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on AEA (main outcome) and inflammatory biomarkers in female dancers. Fifteen participants (5 probiotic, 10 placebo) were included in the final analysis. Serum levels of AEA, LPS, and cytokines (TNF-α, IL-1β, IL-10) were measured using ELISA, and psychological stress responses were evaluated using the Mini-COPE questionnaire. At baseline, a correlation between AEA and LPS was observed (Spearman’s r = 0.9677, p < 0.05). After 12 weeks, no statistically significant differences in AEA, LPS, cytokine levels, or stress-coping strategies were observed between the probiotic and placebo groups (LPS–probiotic: +3.48 EU/L, p = 0.9361; placebo: +56.98 EU/L, p = 0.0694; AEA–probiotic: −1.11 ng/mL, p = 0.9538; placebo: +14.08 ng/mL, p = 0.4749). The direction of change may indicate a trend toward increased inflammation in the absence of probiotics. These results should be viewed as hypothesis generating and warrant confirmation in larger trials.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).